FDA hands down ap­proval for Bris­tol My­er­s' lung can­cer drug from Turn­ing Point buy­out

Bris­tol My­ers Squibb’s $4.1 bil­lion buy­out of Turn­ing Point Ther­a­peu­tics has paid off, with the FDA hand­ing down an ap­proval of the lead can­cer drug in the ac­qui­si­tion.

Re­potrec­tinib, which will now be mar­ket­ed as Aug­ty­ro, has been ap­proved for adult pa­tients with lo­cal­ly ad­vanced or metasta­t­ic ROS1-pos­i­tive non-small cell lung can­cer. It will be a new ri­val to Pfiz­er’s Xalko­ri and Roche’s Ro­z­lytrek in ROS1-pos­i­tive NSCLC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER